Larry Tjoelker
Keine laufenden Positionen mehr
Karriereverlauf von Larry Tjoelker
Ehemalige bekannte Positionen von Larry Tjoelker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NEVIS BRANDS INC. | Technik-/Wissenschafts-/F&E-Leiter | 28.11.2018 | 01.06.2022 |
OMEROS CORPORATION | Corporate Officer/Principal | 01.12.2011 | 01.04.2017 |
XORI Corp.
XORI Corp. BiotechnologyHealth Technology XORI Corp. provides health technology services. It develops technology for the rapid discovery and development of monoclonal antibodies (MAbs). The firm validates the technology on a variety of targets and develops superior products for cancer therapy, immune disorders, and infectious diseases. The company was founded by Nancy Maizels in 2009 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 21.05.2009 | 01.02.2012 |
MACROGENICS, INC. | Corporate Officer/Principal | 01.01.2002 | 01.01.2007 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Corporate Officer/Principal | - | - |
Ausbildung von Larry Tjoelker
University of Pennsylvania | Doctorate Degree |
University of Michigan | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MACROGENICS, INC. | Health Technology |
NEVIS BRANDS INC. | Health Technology |
OMEROS CORPORATION | Health Technology |
Private Unternehmen | 3 |
---|---|
XORI Corp.
XORI Corp. BiotechnologyHealth Technology XORI Corp. provides health technology services. It develops technology for the rapid discovery and development of monoclonal antibodies (MAbs). The firm validates the technology on a variety of targets and develops superior products for cancer therapy, immune disorders, and infectious diseases. The company was founded by Nancy Maizels in 2009 and is headquartered in Seattle, WA. | Health Technology |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
- Börse
- Insiders
- Larry Tjoelker
- Erfahrung